更正：开发血管生成抑制剂有效生物标志物面临的挑战：莫替沙尼的经验。
Correction: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.
出版信息
PLoS One. 2015 Mar 26;10(3):e0121162. doi: 10.1371/journal.pone.0121162. eCollection 2015.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0108048.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0108048。]
相似文献
1
Correction: challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.更正：开发血管生成抑制剂有效生物标志物面临的挑战：莫替沙尼的经验。
PLoS One. 2015 Mar 26;10(3):e0121162. doi: 10.1371/journal.pone.0121162. eCollection 2015.
2
Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy.更正：HP1β是乳腺癌预后和PARP抑制剂治疗的生物标志物。
PLoS One. 2015 Apr 13;10(4):e0124853. doi: 10.1371/journal.pone.0124853. eCollection 2015.
3
Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.更正：为类风湿关节炎患者开发心血管风险计算器的挑战。
PLoS One. 2017 Apr 7;12(4):e0175605. doi: 10.1371/journal.pone.0175605. eCollection 2017.
4
Correction: Detection of a Serum Siderophore by LC-MS/ MS as a Potential Biomarker of Invasive Aspergillosis.更正：通过液相色谱-质谱联用技术检测血清铁载体作为侵袭性曲霉病的潜在生物标志物
PLoS One. 2016 May 10;11(5):e0155451. doi: 10.1371/journal.pone.0155451. eCollection 2016.
5
Correction: RNA-Seq Reveals the Angiogenesis Diversity between the Fetal and Adults Bone Mesenchyme Stem Cell.更正：RNA测序揭示胎儿和成人间充质干细胞的血管生成差异
PLoS One. 2016 Jul 8;11(7):e0159221. doi: 10.1371/journal.pone.0159221. eCollection 2016.
6
Correction: The Male Fetal Biomarker INSL3 Reveals Substantial Hormone Exchange between Fetuses in Early Pig Gestation.更正：雄性胎儿生物标志物松弛素样肽3揭示了猪妊娠早期胎儿之间大量的激素交换。
PLoS One. 2016 Jun 15;11(6):e0157954. doi: 10.1371/journal.pone.0157954. eCollection 2016.
7
Correction: pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.更正：磷酸化黏着斑激酶酪氨酸397（pFAK-Y397）过表达作为转移性骨肉瘤患者的预后和预测生物标志物。
PLoS One. 2017 Nov 29;12(11):e0188991. doi: 10.1371/journal.pone.0188991. eCollection 2017.
8
Correction: Metabolomics based predictive biomarker model of ARDS: A systemic measure of clinical hypoxemia.更正：基于代谢组学的急性呼吸窘迫综合征预测生物标志物模型：临床低氧血症的系统测量
PLoS One. 2018 Feb 21;13(2):e0193474. doi: 10.1371/journal.pone.0193474. eCollection 2018.
9
Correction: Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis.更正：剖析CCR2-CCL2轴在肿瘤存活和血管生成中的自分泌和旁分泌作用。
PLoS One. 2018 Apr 12;13(4):e0195170. doi: 10.1371/journal.pone.0195170. eCollection 2018.
10
Correction: Adipose Tissue-Derived Mesenchymal Stem Cells in Long-Term Dialysis Patients Display Downregulation of PCAF Expression and Poor Angiogenesis Activation.更正：长期透析患者脂肪组织来源的间充质干细胞显示PCAF表达下调和血管生成激活不良。
PLoS One. 2016 Jun 6;11(6):e0157282. doi: 10.1371/journal.pone.0157282. eCollection 2016.
本文引用的文献
1
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience.开发血管生成抑制剂有效生物标志物面临的挑战：莫特沙尼的经验
PLoS One. 2014 Oct 14;9(10):e108048. doi: 10.1371/journal.pone.0108048. eCollection 2014.
Zotero 插件